Jubilant Pharmova Limited has informed the Exchange regarding Appointment of Deloitte Touche Tohmatsu India LLP as Other of the company w.e.f. July 29, 2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova's Board of Directors, at a meeting held on July 29, 2025, approved two key items. First, Deloitte Touche Tohmatsu India LLP has been re-appointed as the Internal Auditor of the company for a period of 3 consecutive years, covering FY 2025-26 to FY 2027-28. Second, the company has granted 1,21,560 Stock Options/Restricted Stock Units (RSUs) to eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. The exercise price has been set at Re. 1 per share (face value), with vesting periods ranging from 1 year to the end of FY 2028 based on performance criteria.
These are routine governance and employee compensation actions with no material impact expected on the stock price. The Deloitte re-appointment signals continuity in internal audit oversight, while the ESOP grant at face value is a low-cost employee incentive that may result in minor dilution upon vesting.